Država: Nova Zelandija
Jezik: angleščina
Source: Medsafe (Medicines Safety Authority)
Omalizumab 150mg
Novartis New Zealand Ltd
Omalizumab 150 mg
150 mg
Powder for injection with diluent
Active: Omalizumab 150mg Excipient: Histidine Histidine hydrochloride Polysorbate 20 Sucrose Water for injection
Combination pack, powder + diluent, 1 dose unit
Prescription
Prescription
Novartis Pharma SAS
Xolair is indicated for the reduction of asthma exacerbations and control of asthma symptoms when given as add-on therapy for adult and adolescent patients, 6 years and older, with severe persistent allergic asthma who have IgE > 30 IU/ml, a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled iwth inhaled corticosteroids.
Package - Contents - Shelf Life: Ampoule, glass, 2 mL colourless type I - 1 dose units - 60 months from date of manufacture stored at or below 30°C - Ampoule, glass, diluent - 1 dose units - 60 months from date of manufacture stored at or below 30°C - Combination pack, powder + diluent - 1 dose units - 48 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze) 8 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) 4 hours reconstituted (not refrigerated) stored at or below 30°C. (physical/chemical properties only) 2 hours reconstituted (not refrigerated) stored at or below 25°C. (physical/chemical/microbioloigical properties) - Vial, glass, powder - 1 dose units - 48 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze)
2000-06-07
__________________________________________________________________________________________________ XOLAIR 1 XOLAIR ® _Omalizumab (rch) _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Xolair . It does not contain all the available information . It does not take the place of talking to your doctor, pharmacist or healthcare provider. The information in this leaflet was last updated on the date listed on the final page. More recent information on the medicine may be available. YOU SHOULD ENSURE THAT YOU SPEAK TO YOUR PHARMACIST OR DOCTOR TO OBTAIN THE MOST UP TO DATE INFORMATION ON THE MEDICINE. YOU CAN ALSO DOWNLOAD THE MOST UP TO DATE LEAFLET FROM WWW.MEDSAFE.GOVT.NZ Those updates may contain important information about the medicine and its use of which you should be aware. All medicines have risks and benefits. Your doctor has weighed the risks of you having Xolair against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT HAVING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET. You may need to read it again. WHAT XOLAIR IS USED FOR ALLERGIC ASTHMA Xolair is used to prevent or relieve the symptoms of allergic asthma in people who are already using preventer puffers containing steroids. Asthma is a disease where the lining of the lungs becomes inflamed (red and swollen), making it difficult to breathe. This may be due to a reaction to house dust mites, smoke or other irritants. This medicine can be used in adults and in children aged 6 years or over for the treatment of allergic asthma. CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (NASAL POLYPS) Xolair is used to treat nasal polyps in adults (18 years of age and older) whose severe disease is not well controlled with their current nasal polyps medicines. Xolair helps reduce the size of the polyps and improves symptoms caused by nasal polyps including nasal congestion, loss of sense of smell, post-nasal drip and runny nose. This medicine can be used in adults aged 18 Preberite celoten dokument
XOLAIR® solution for injection Page 1 of 39 XOLAIR ® OMALIZUMAB 1. PRODUCT NAME Xolair 75 mg solution for injection in pre-filled syringe Xolair 150 mg solution for injection in pre-filled syringe Xolair 150 mg powder vial and diluent for solution for injection* * _Not marketed strength or dosage form_ 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Solution for injection in pre-filled syringe: Each pre-filled syringe of 0.5 mL contains 75 mg of omalizumab. Each pre-filled syringe of 1 mL contains 150 mg of omalizumab. Powder and diluent for solution for injection: One vial of Xolair 150 mg powder and diluent for solution for injection contains 150 mg of omalizumab. Reconstituted Xolair contains 125 mg/mL of omalizumab (150 mg in 1.2 mL). Omalizumab is a humanized monoclonal antibody manufactured from a mammalian cell line. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection in pre-filled syringe: Clear to slightly opalescent, colorless to pale brownish-yellow solution in a pre-filled syringe. Powder and diluent for solution for injection: Powder: white to off-white lyohilisate in a glass vial. Diluent: clear and colorless solution in a glass ampoule 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Allergic Asthma Xolair (omalizumab) is indicated for the reduction of asthma exacerbations and control of asthma symptoms when given as add-on therapy for adult and adolescent patients, 6 years and older, with severe persistent allergic asthma who have IgE ≥ 30 IU/mL, a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. XOLAIR® solution for injection Page 2 of 39 Chronic rhinosinusitis with nasal polyps (CRSwNP) Xolair is indicated as add-on treatment in adult patients (18 years of age and above) for the treatment of severe CRSwNP with inadequate response to intranasal corticosteroids. Recommended dosing is determined by serum immunoglobulin E levels and body weight corresponding Preberite celoten dokument